CSF2 and Sepsis: A study from 2009 investigating 280 neonates ≤ 31 weeks' gestation demonstrated that even higher doses of postnatal prophylactic GM-CSF (10 μg/kg per day administrated subcutaneously on 5 consecutive days) did not reduce sepsis or improve survival or short-term outcomes (85).